Characteristics of cultured human melanocytes from different stages of tumor progression

  • Ulrich Rodeck
  • Meenhard Herlyn
Part of the Cancer Treatment and Research book series (CTAR, volume 43)


Early studies on chemically induced carcinomas in animals suggested that tumorigenesis is not a one-step phenomenon but rather represents a sequence of events leading to increasingly aggressive neoplasms [1, 2]. The concept of distinct sequential stages in the development of malignant cells has gained wide acceptance for both experimentally induced and sporadic malignancies [3].


Melanoma Cell Human Melanoma Cell Human Melanocyte Metastatic Melanoma Cell Melanocytic Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Foulds L: Mammary tumours in hybrid mice: Growth and progression of spontaneous tumors. Br J Cancer 3:345–375, 1949.PubMedCrossRefGoogle Scholar
  2. 2.
    Foulds L: Neoplastic development, vol. I. New York: Academic Press, 1969, pp. 69–75.Google Scholar
  3. 3.
    Farber E, Cameron, R: The sequential analysis of cancer development. In: Advances in cancer research, vol. 31. New York: Academic Press, 1980, pp. 125–226.CrossRefGoogle Scholar
  4. 4.
    Clark WH, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M: A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Human Pathol 15:1147–1165, 1984.CrossRefGoogle Scholar
  5. 5.
    Elder DE, Clark WH: Developmental biology of malignant melanoma. In: Pigment cell, vol. 8. Karger Basel, 1987, pp. 1–28.Google Scholar
  6. 6.
    Clark WH, Elder DE, Van Horn M: The biologic forms of malignant melanoma. Human Pathol 17:443–450, 1986.CrossRefGoogle Scholar
  7. 7.
    Herlyn M, Herlyn D, Elder DE, Bondi E, LaRossa D, Hamilton R, Sears H, Balaban G, Guerry D, Clark WH, Koprowski H: Phenotypic characteristics of cells derived from precursors of human melanoma. Cancer Res 43:5502–5508, 1983.PubMedGoogle Scholar
  8. 8.
    Herlyn M, Thurin J, Balaban G, Bennicelli J, Herlyn D, Elder DE, Bondi E, Guerry D, Nowell P, Clark WH, Koprowski H: Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45:5670–5676, 1985.PubMedGoogle Scholar
  9. 9.
    Eisinger M, Marko O, Ogata S-I, Old LJ: Growth regulation of human melanocytes: Mitogenic factors in extracts of melanoma, astrocytoma, and fibroblast cell lines. Science 229:984–986, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Halaban R, Ghosh S, Duray P, Kirkwood JM, Lerner AB: Human melanocytes cultured from nevi and melanomas. J Invest Dermatol 87:95–101, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Gilchrest BA, Treloar V, Grassi AM, Yaar M, Szabo G, Flynn E: Characteristics of cultivated adult human nevocellular nevus cells. J Invest Dermatol 87:102–107, 1986.PubMedCrossRefGoogle Scholar
  12. 12.
    Mancianti ML, Herlyn M, Weil D, Jambrosic J, Rodeck U, Becker D, Diamond L, Clark WH, Koprowski H: Growth and phenotypic characteristics of human nevus cells in culture. J Invest Dermatol 90:134–141, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Herlyn M, Rodeck U, Mancianti ML, Cardillo F, Lang A, Ross A, Jambrosic J, Koprowski H: Expression of melanoma-associated antigens in rapidly dividing human melanocytes. Cancer Res 47:3057–3061, 1987.PubMedGoogle Scholar
  14. 14.
    Halaban R, Alfano FD: Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 20:447–450, 1984.PubMedCrossRefGoogle Scholar
  15. 15.
    Rodeck U, Herlyn M, Menssen H, Furlanetto RW, Koprowski H: Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 40:687–690, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    Eisinger M, Marko O: Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 79:2018–2022, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Halaban R, Ghosh S, Baird A: bFGF is the putative natural growth factor for human melanocytes. In Vitro 23:47–52, 1987.Google Scholar
  18. 18.
    Wilkins L, Gilchrest GA, Szabo G, Weinstein R, Maciag T: The stimulation of normal human melanocyte proliferation in vitro by melanocyte growth factor from bovine brain. J Cell Physiol 122:350–361, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Richmond A, Fine R, Murray D, Lawson DH, Priest JH: Growth factor and cytogenic abnormalities in cultured nevi and malignant melanomas. J Invest Dermatol 86:295–302, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313:745–747, 1985.PubMedCrossRefGoogle Scholar
  21. 21.
    Heldin C-H, Westermark B: Growth factors: Mechanism of action and relation to oncogenes. Cell 37:9–20, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Holley RW: Control of growth of mammalian cells in culture. Nature 258:487–490, 1975.PubMedCrossRefGoogle Scholar
  23. 23.
    Marquardt H, Todaro G: Human transforming growth factor—production by a melanoma cell line, purification, and initial characterization. J Biol Chem 257:5220–5227, 1982.PubMedGoogle Scholar
  24. 24.
    Richmond A, Lawson DH, Nixon DW, Stedman NJ, Stevens S, Chawla RK: Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. Cancer Res 43:2106–2112, 1983.PubMedGoogle Scholar
  25. 25.
    Richmond A, Lawson DH, Nixon DW, Chawla RK: Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res 45:6390–6394, 1985.PubMedGoogle Scholar
  26. 26.
    DeLarco JE, Pigott DA, Lazarus JA: Ectopic peptides released by a human melanoma cell line that modulate the transformed phenotype. Proc Natl Acad Sci USA 82:5015–5019, 1985.CrossRefGoogle Scholar
  27. 27.
    Kim MK, Warren TC, Kimball ES: Purification and characterization of a low molecular weight transforming growth factor from the urine of melanoma patients. J Biol Chem 260:9237–9243, 1985.PubMedGoogle Scholar
  28. 28.
    Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin C-H, Herlyn M, Rodeck U, Koprowski H: Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci USA 83:7197–7200, 1986.PubMedCrossRefGoogle Scholar
  29. 29.
    Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin D: Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 129:273–276, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Ogata S, Furuhashi Y, Eisinger M: Growth stimulation of human melanocytes: Identification and characterization of melanoma-derived melanocyte growth factor. Biochem Biophys Res Commun 146:1204–1211, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Fidler IJ, Hart IR: Biological diversity in metastatic neoplasms: Origins and implications. Science (Washington, DC) 217:998–1003, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Nicolson GL, Milas L (eds): Cancer invasion and metastasis. Biological and therapeutic aspects. New York: Raven Press, 1984.Google Scholar
  33. 33.
    Liotta LA, Hart IR (eds): Tumor invasion and metastasis. The Hague, Boston: Martinus Nijhoff, 1982.Google Scholar
  34. 34.
    Herlyn M, Koprowski H. Melanoma antigens: Immunological and biological characterization and clinical significance. Ann Rev Immunol 6:283–308, 1988.CrossRefGoogle Scholar
  35. 35.
    Matyas GR, Evers DC, Radinsky R, Morre DJ: Fibronectin binding to gangliosides and rat liver plasma membranes. Exp Cell Res 162:296–318, 1986.PubMedCrossRefGoogle Scholar
  36. 36.
    Cheresh DA, Klier FG: Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol 102:1887–1897, 1986.PubMedCrossRefGoogle Scholar
  37. 37.
    Cheresh DA, Harper JR, Schulz G, Reisfeld RA: Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767–5771, 1984.PubMedCrossRefGoogle Scholar
  38. 38.
    Rosenberg JM, Reisfeld RA, Sander DJ, Cheresh DA: A specific sialyltransferase is responsible for the synthesis of GD3, a ganglioside preferentially expressed on human metastatic melanoma cells. Proc Am Assoc Cancer Res 27:1, 1986.Google Scholar
  39. 39.
    Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH, Koprowski H: GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 208:17–22, 1986.PubMedCrossRefGoogle Scholar
  40. 40.
    Dippold WG, Knuth A, Meyer zum Büschenfelde K-H: Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44:806–810, 1984.PubMedGoogle Scholar
  41. 41.
    Iliopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH, Koprowski H, Herlyn D: Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. Submitted.Google Scholar
  42. 42.
    Garbisa S, Pozatti R, Muschel R, Libbey NP, Spremulli EN, Calabresi P: Secretion of type IV collagenolytic protease and metastatic phenotype: Induction by transfection with c-Ha-ras but not c-Haras plus Ad2-Ela. Cancer Res 47:1523–1528, 1987.PubMedGoogle Scholar
  43. 43.
    Duffi MJ, O’Grady PO: Plasminogen activator and cancer. Eur J Cancer Clin Oncol 20:577–582, 1984.CrossRefGoogle Scholar
  44. 44.
    Cajot J, Kruithof EKO, Schleuning W-D, Sordat B, Bachmann F: Plasminogen activator, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 38:719–727, 1986.PubMedCrossRefGoogle Scholar
  45. 45.
    Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K: Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int J Cancer 30:669–673, 1982.PubMedCrossRefGoogle Scholar
  46. 46.
    Turpeenniemi-Hujanen T, Thorgeirson UP, Hart IP, Grant SS, Liotta LA: Expression of collagenase type IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 75:99–103, 1985.PubMedGoogle Scholar
  47. 47.
    Koprowski H, Steplewski Z, Herlyn D, Herlyn M: Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 75:3405–3409, 1978.PubMedCrossRefGoogle Scholar
  48. 48.
    Reisfeld RA, Cheresh DA: Human tumor antigens. Adv Immunol 40:323–377, 1987.PubMedCrossRefGoogle Scholar
  49. 49.
    Bumol TF, Reisfeld RA: Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci USA 79:1245–1249, 1982.PubMedCrossRefGoogle Scholar
  50. 50.
    de Vries JE, Keizer GD, teVelde AA, Voordouw A, Ruiter D, Rumke P, Spits H, Figdor CG: Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer 38:465–473, 1986.PubMedCrossRefGoogle Scholar
  51. 51.
    Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ: GD3—a prominent ganglioside of human melanoma: Detection and characterization by mouse monoclonal antibody. J Exp Med 155:1133–1147, 1982.PubMedCrossRefGoogle Scholar
  52. 52.
    Natali PG, Nicotra MR, Belocci M, Cavaliere R, Bigotti A: Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocyte origin. Int J Cancer 35: 461–467, 1985.PubMedCrossRefGoogle Scholar
  53. 53.
    Brown JP, Woodbury RR, Hart CE, Hellstrom I, Hellstrom KE: Structural characterization of human melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78:539–545, 1980.CrossRefGoogle Scholar
  54. 54.
    Weiss SW, Langloss JM, Enzinger FM: Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 49:299–308, 1983.PubMedGoogle Scholar
  55. 55.
    Ross AH, Grob P, Bothwell MA, Elder DE, Ernst CS, Marano N, Ghrist BFD, Stemp CC, Herlyn M, Atkinson B, Koprowski H: Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci USA 81:6681–6685, 1984.PubMedCrossRefGoogle Scholar
  56. 56.
    Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross AH, Nowell PC: Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 1:297–302, 1985.CrossRefGoogle Scholar
  57. 57.
    Thomson TM, Mattes M, Ranx L, Old LJ, Lloyd KO: Pigmentation-associated glycoprotein of human melanomas and melanocytes: Definition with a mouse monoclonal antibody. J Invest Dermatol 85:169–174, 1985.PubMedCrossRefGoogle Scholar
  58. 58.
    Hayashibe K, Mishima Y, Ichihashi M, Kawai M: Melanosomal antigenic expression on the cell surface and intra-cellular subunits within melanogenic compartments of pigment cells: Analysis by anti-melanosome-associated monoclonal antibody. J Invest Dermatol 87:89–94, 1986.PubMedCrossRefGoogle Scholar
  59. 59.
    Winchester RG, Wang C-Y, Gibofsky A, Kunkle HG, Lloyd KO, Old LJ: Expression of la-like antigens on cultured malignant melanoma cell lines. Proc Natl Acad Sci USA 75:6235–6239, 1978.PubMedCrossRefGoogle Scholar
  60. 60.
    Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56:461–474, 1987.PubMedGoogle Scholar
  61. 61.
    Gaynor R, Irie R, Morton D, Herschmann HR: S-100 protein is present in cultured human malignant melanomas. Nature 286:400–401, 1980.PubMedCrossRefGoogle Scholar
  62. 62.
    Ross AH, Herlyn M, Maul GH, Koprowski H, Bothwell M, Chao M, Pleasure D, Sonnenfeld KH: The nerve growth factor receptor in normal and transformed neural crest cells. Ann NY Acad Sci 486:115–123, 1986.PubMedCrossRefGoogle Scholar
  63. 63.
    Rodeck U, Herlyn M, Koprowski H: Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J Cell Biochem 35:315–320, 1987.PubMedCrossRefGoogle Scholar
  64. 64.
    Guerry D, Alexander MA, Herlyn M, Zehngebot LM, Mitchell KF, Zmijewski CM, Lusk EJ: HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest 73:267–271, 1984.PubMedCrossRefGoogle Scholar
  65. 65.
    Fossati G, Taramelli D, Dalsari A, Bogdanovich G, Andreola S, Parmiani G: Primary but not metastatic human melanoma expressing DR antigens stimulate autologous lymphocytes. Int J Cancer 33:591–597, 1984.PubMedCrossRefGoogle Scholar
  66. 66.
    Houghton AN, Cordon-Cardo C, Eisinger M: Differentiation antigens of melanoma and melanocytes. Int Rev Exp Pathol 28:317–329, 1986.Google Scholar
  67. 67.
    Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ: Surface antigens of melanoma and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigenic expression in cultured cells and tissues. Cancer Res 45:4401–4411, 1985.PubMedGoogle Scholar
  68. 68.
    Holzmann B, Bröcker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmüller G, Johnson JP: Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotype. Int J Cancer 39:466–471, 1987.PubMedCrossRefGoogle Scholar
  69. 69.
    Thompson JJ, Herlyn M, Elder DE, Clark WH, Steplewski Z, Koprowski H: Use of monoclonal antibodies in detection of melanoma-associated antigens in cultured rapidly dividing human melanocytes. Am J Pathol 107:357–361, 1982.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1988

Authors and Affiliations

  • Ulrich Rodeck
  • Meenhard Herlyn

There are no affiliations available

Personalised recommendations